BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30577224)

  • 1. Optimal Settings for Double Filtration Plasmapheresis With Targeted Removal Rate of Preexisting Antibody in Antibody-Incompatible Kidney Transplant.
    Iwami D; Miura M; Chiba Y; Ota M; Matsumoto T; Hotta K; Sasaki H; Hirose T; Harada H; Shinohara N
    Transplant Proc; 2018 Dec; 50(10):3478-3482. PubMed ID: 30577224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of theefficacy of removal of anti-ABO and anti-gal antibodies by double filtration plasmapheresis.
    Kobayashi T; Yokoyama I; Morozumi K; Nagasaka T; Hayashi S; Uchida K; Takagi H; Nakao A
    Xenotransplantation; 2000 May; 7(2):101-8. PubMed ID: 10961294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-filtration plasmapheresis.
    Tanabe K
    Transplantation; 2007 Dec; 84(12 Suppl):S30-2. PubMed ID: 18162985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double filtration plasmapheresis in antibody-incompatible kidney transplantation.
    Higgins R; Lowe D; Hathaway M; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Chen K; Krishnan N; Hamer R; Zehnder D; Briggs D
    Ther Apher Dial; 2010 Aug; 14(4):392-9. PubMed ID: 20649760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoagglutinin removal by plasma centrifugation or filtration (single or double): A prospective study in a single center.
    Naciri Bennani H; Noble J; Chevallier E; Terrec F; Motte L; Giroux-Lathuile C; Bugnazet M; Imerzoukene F; Janbon B; Malvezzi P; Rostaing L; Jouve T
    J Clin Apher; 2021 Feb; 36(1):149-160. PubMed ID: 33230824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-tolerability of double-filtration plasmapheresis in antibody-incompatible kidney transplant candidates.
    Hebibi H; Weclawiak H; Rostaing L; Beaudreuil S; Allal A; François H; Durrbach A; Kamar N
    Saudi J Kidney Dis Transpl; 2015 Mar; 26(2):297-301. PubMed ID: 25758878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More selective removal of myeloperoxidase-anti-neutrophil cytoplasmic antibody from the circulation of patients with vasculitides using a novel double-filtration plasmapheresis therapy.
    Gong D; Ji D; Xu B; Liu Z
    Ther Apher Dial; 2013 Feb; 17(1):93-8. PubMed ID: 23379500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S; Hwang E; Park S; Park U; Kim H; Cho W
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of immunoglobulin M reduction via therapeutic dose of simple plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia.
    Miyamoto Y; Hamasaki Y; Matsumoto A; Doi K; Noiri E; Nangaku M
    J Clin Apher; 2018 Oct; 33(5):611-615. PubMed ID: 30188580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience of ABO-incompatible living kidney transplantation after double filtration plasmapheresis.
    Ishikawa A; Itoh M; Ushlyama T; Suzuki K; Fujita K
    Clin Transplant; 1998 Apr; 12(2):80-3. PubMed ID: 9575393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double filtration plasmapheresis for children with different types of critical kidney diseases: a single-center retrospective cohort study.
    Zhang Y; Xie Q; Chen Y; Yang J; Huang S; Deng L; Zhou J
    Transl Pediatr; 2023 Mar; 12(3):354-363. PubMed ID: 37035407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case report of efficiency of double filtration plasmapheresis in treatment of Goodpasture's syndrome.
    Hajime N; Michiko A; Atsunori K; Tatsuo K; Yuko N; Naoki O; Katsuhiko S
    Ther Apher Dial; 2009 Aug; 13(4):373-7. PubMed ID: 19695077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum albumin concentration of supplementation fluid for double filtration plasmapheresis.
    Mineshima M; Agishi T; Hasuo Y; Era K; Suzuki T; Teraoka S; Ota K
    Artif Organs; 1992 Oct; 16(5):510-3. PubMed ID: 10078302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipients.
    Parmentier SP; Rosenkranz E; Schirutschke H; Opgenoorth M; Quick C; Hoelig K; Rosner A; Hohenstein B; Hugo C; Passauer J
    Atheroscler Suppl; 2017 Nov; 30():253-256. PubMed ID: 29096846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous monitoring of blood volume in double filtration plasmapheresis.
    Mineshima M; Eguchi K; Horibe K; Yokoi R; Kaneko I; Kimata N; Sanaka T; Nihei H; Agishi T
    ASAIO J; 1998; 44(5):M465-9. PubMed ID: 9804474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Removal ability of immunoglobulins in plasma exchange and double-filtration plasmapheresis].
    Tagawa Y; Yuki N
    Rinsho Shinkeigaku; 1997 May; 37(5):410-2. PubMed ID: 9294330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitization with the Use of an Antibody Removal-Free Protocol in ABO-Incompatible Kidney Transplant Recipients with a Low Anti-A/B Antibody Titer.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):982-986. PubMed ID: 29731097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ability to remove immunoglobulins and antiganglioside antibodies by double filtration plasmapheresis in Guillain-Barré syndrome: is it equivalent to plasma exchange?
    Tagawa Y; Yuki N; Hirata K
    Ther Apher; 1997 Nov; 1(4):336-9. PubMed ID: 10225726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of therapeutic plasma exchange and double filtration plasmapheresis on hemostasis in renal transplant recipients.
    Vatazin AV; Zulkarnaev AB
    Ter Arkh; 2018 Jun; 90(6):22-27. PubMed ID: 30701900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.